Drug repositioning of polaprezinc for bone fracture healing

Commun Biol. 2022 May 16;5(1):462. doi: 10.1038/s42003-022-03424-7.

Abstract

Fractures and related complications are a common challenge in the field of skeletal tissue engineering. Vitamin D and calcium are the only broadly available medications for fracture healing, while zinc has been recognized as a nutritional supplement for healthy bones. Here, we aimed to use polaprezinc, an anti-ulcer drug and a chelate form of zinc and L-carnosine, as a supplement for fracture healing. Polaprezinc induced upregulation of osteogenesis-related genes and enhanced the osteogenic potential of human bone marrow-derived mesenchymal stem cells and osteoclast differentiation potential of mouse bone marrow-derived monocytes. In mouse experimental models with bone fractures, oral administration of polaprezinc accelerated fracture healing and maintained a high number of both osteoblasts and osteoclasts in the fracture areas. Collectively, polaprezinc promotes the fracture healing process efficiently by enhancing the activity of both osteoblasts and osteoclasts. Therefore, we suggest that drug repositioning of polaprezinc would be helpful for patients with fractures.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carnosine* / analogs & derivatives
  • Carnosine* / pharmacology
  • Drug Repositioning
  • Fracture Healing
  • Humans
  • Mice
  • Organometallic Compounds
  • Zinc / pharmacology
  • Zinc Compounds

Substances

  • Organometallic Compounds
  • Zinc Compounds
  • polaprezinc
  • Carnosine
  • Zinc